JAMA (Journal of the American Medical Association)
Open in Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
Show more📈 Analytical overview of Telegram channel JAMA (Journal of the American Medical Association)
Channel JAMA (Journal of the American Medical Association) (@jamaupdates) in the English language segment is an active participant. Currently, the community unites 16 209 subscribers, ranking 1 478 in the Medicine category and 2 316 in the USA region.
📊 Audience metrics and dynamics
Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 16 209 subscribers.
According to the latest data from 28 August, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 341 over the last 30 days and by 9 over the last 24 hours, overall reach remains high.
- Verification status: Not verified
- Engagement rate (ER): The average audience engagement rate is 4.32%. Within the first 24 hours after publication, content typically collects 2.11% reactions from the total number of subscribers.
- Post reach: On average, each post receives 700 views. Within the first day, a publication typically gains 342 views.
- Reactions and interaction: The audience actively supports content: the average number of reactions per post is 1.
- Thematic interests: Content is focused on key topics such as patient, disease, treatment, drug, guideline.
📝 Description and content policy
The author describes the resource as a platform for expressing subjective opinions:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
Thanks to the high frequency of updates (latest data received on 29 August, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.
16 209
Subscribers
+924 hours
+677 days
+34130 days
Data loading in progress...
Similar Channels
Tags Cloud
Incoming and Outgoing Mentions
---
---
---
---
---
---
Attracting Subscribers
August '26
August '26
+343
in 0 channels
July '26
+440
in 0 channels
Get PRO
June '26
+422
in 0 channels
Get PRO
May '26
+584
in 0 channels
Get PRO
April '26
+437
in 0 channels
Get PRO
March '26
+217
in 0 channels
Get PRO
February '26
+247
in 0 channels
Get PRO
January '26
+321
in 0 channels
Get PRO
December '25
+277
in 0 channels
Get PRO
November '25
+366
in 2 channels
Get PRO
October '25
+164
in 0 channels
Get PRO
September '25
+12
in 0 channels
Get PRO
August '25
+29
in 0 channels
Get PRO
July '25
+30
in 0 channels
Get PRO
June '25
+17
in 0 channels
Get PRO
May '25
+9
in 0 channels
Get PRO
April '25
+5
in 0 channels
Get PRO
March '25
+17
in 0 channels
Get PRO
February '25
+12
in 0 channels
Get PRO
January '25
+18
in 1 channels
Get PRO
December '24
+237
in 0 channels
Get PRO
November '24
+1 122
in 0 channels
Get PRO
October '24
+1 120
in 0 channels
Get PRO
September '24
+1 527
in 1 channels
Get PRO
August '24
+1 128
in 1 channels
Get PRO
July '24
+1 216
in 0 channels
Get PRO
June '24
+781
in 1 channels
Get PRO
May '24
+797
in 1 channels
Get PRO
April '24
+808
in 1 channels
Get PRO
March '24
+821
in 2 channels
Get PRO
February '24
+753
in 1 channels
Get PRO
January '24
+768
in 0 channels
Get PRO
December '23
+716
in 1 channels
Get PRO
November '23
+96
in 1 channels
Get PRO
October '23
+86
in 0 channels
Get PRO
September '23
+73
in 0 channels
Get PRO
August '23
+90
in 0 channels
Get PRO
July '23
+107
in 0 channels
Get PRO
June '23
+105
in 0 channels
Get PRO
May '23
+169
in 0 channels
Get PRO
April '23
+128
in 0 channels
Get PRO
March '23
+84
in 0 channels
Get PRO
February '23
+75
in 0 channels
Get PRO
January '23
+71
in 0 channels
Get PRO
December '22
+74
in 0 channels
Get PRO
November '22
+149
in 0 channels
Get PRO
October '22
+90
in 0 channels
Get PRO
September '22
+138
in 0 channels
Get PRO
August '22
+77
in 0 channels
Get PRO
July '22
+50
in 0 channels
Get PRO
June '22
+96
in 0 channels
Get PRO
May '22
+75
in 0 channels
Get PRO
April '22
+80
in 0 channels
Get PRO
March '22
+65
in 0 channels
Get PRO
February '22
+26
in 0 channels
Get PRO
January '22
+56
in 0 channels
Get PRO
December '21
+44
in 0 channels
Get PRO
November '21
+39
in 0 channels
Get PRO
October '21
+61
in 0 channels
Get PRO
September '21
+66
in 0 channels
Get PRO
August '21
+65
in 0 channels
Get PRO
July '21
+96
in 0 channels
Get PRO
June '21
+120
in 0 channels
Get PRO
May '21
+130
in 0 channels
Get PRO
April '21
+812
in 0 channels
| Date | Subscriber Growth | Mentions | Channels | |
| 29 August | +13 | |||
| 28 August | +9 | |||
| 27 August | +12 | |||
| 26 August | +16 | |||
| 25 August | +3 | |||
| 24 August | +7 | |||
| 23 August | +9 | |||
| 22 August | +12 | |||
| 21 August | +24 | |||
| 20 August | +15 | |||
| 19 August | +11 | |||
| 18 August | +10 | |||
| 17 August | +17 | |||
| 16 August | +7 | |||
| 15 August | +14 | |||
| 14 August | +14 | |||
| 13 August | +9 | |||
| 12 August | +14 | |||
| 11 August | +19 | |||
| 10 August | +7 | |||
| 09 August | +15 | |||
| 08 August | +18 | |||
| 07 August | +2 | |||
| 06 August | +16 | |||
| 05 August | +5 | |||
| 04 August | +13 | |||
| 03 August | +11 | |||
| 02 August | +9 | |||
| 01 August | +12 |
Channel Posts
Causal Endotype–Based Classification of Myocardial Infarction
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853495
This study characterizes the distribution and clinical features of myocardial infarction causal endotypes in a large contemporary cohort with a descriptive assessment of associated 1-year outcomes.
| 2 | The Evolving Process of Myocardial Infarction Classification
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853496
Acute myocardial infarction (MI) has a clear pathological definition: the death of myocardial cells caused by prolonged ischemia. However, in a clinical setting, it is considerably more difficult to establish the diagnosis of MI. In 2007, a consortium of the European Society of Cardiology, the American College of Cardiology Foundation, the American Heart Association, and the World Heart Federation proposed the Universal Definition of Myocardial Infarction (UDMI) to guide diagnosis and classification of MI. Advances in understanding the pathophysiological mechanisms of myocardial injury, advances in diagnostic techniques as well as signals from daily practice regarding performance, and problems of the UDMI led to 3 subsequent iterations of the consensus document. The most recent version, the fourth UDMI, was published in 2018. The current UDMI-based clinical definition of MI requires a combination of a rise and fall in high-sensitivity cardiac troponin, with at least 1 value above the 99th percentile upper reference limit, and evidence of acute myocardial ischemia that includes 1 or more of the following: presence of symptoms, new ischemic changes on electrocardiography, development of pathological Q waves, imaging evidence of new loss of viable myocardium, a new regional wall-motion abnormality, or identification of a coronary thrombus. Although the fourth UDMI provided better pathophysiology-oriented MI diagnoses and classifications than prior versions, the increased complexity of the classification inevitably negatively impacts operational utility and ease of use in daily practice. | 238 |
| 3 | LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2853273
This trial evaluated whether starting evolocumab before percutaneous coronary intervention improved low-density lipoprotein cholesterol target achievement and clinical outcomes after acute myocardial infarction. | 222 |
| 4 | Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction
https://jamanetwork.com/journals/jama/fullarticle/2853274
This prospective randomized open, blinded end-point adjudication study examines evolocumab as first-line therapy vs standard care in patients with high-risk acute myocardial infarction undergoing percutaneous coronary intervention. | 223 |
| 5 | LDL-C Lowering After Myocardial Infarction
https://jamanetwork.com/journals/jama/fullarticle/2853275
When statins first emerged as a potent treatment for elevated low-density lipoprotein cholesterol (LDL-C), the logical population to test was patients with coronary heart disease (CHD) and high LDL-C, providing definitive proof causally linking LDL-C to CHD. Additional statin trials extended the evidence base, demonstrating that clinical benefit from statins could be achieved even in patients with lower LDL-C thresholds. The early statin trials excluded individuals with recent myocardial infarction (MI) in the preceding 4 to 6 months, potentially because of clinical instability or from reasoning that early thrombotic events may not be modifiable from altering the pathology in the artery wall through lowering LDL-C. | 200 |
| 6 | Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50% Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2853394
This trial tested whether implantable cardioverter-defibrillators (ICDs) reduce sudden cardiac death (SCD) or hemodynamically significant ventricular arrhythmia (HSVA) in patients with a left ventricular ejection fraction (LVEF) of 36% to 50% and myocardial scar. | 370 |
| 7 | CMR to Guide Defibrillator Implantation for LVEF
https://jamanetwork.com/journals/jama/fullarticle/2853395
This randomized clinical trial compares the effects of an implantable cardioverter-defibrillator vs an implantable loop recorder on sudden cardiac death risk or hemodynamically significant ventricular arrhythmia in patients with a left ventricular ejection fraction of 36% to 50% and a myocardial scar. | 367 |
| 8 | Implantable Cardioverter-Defibrillators for Patients With an LVEF >35%
https://jamanetwork.com/journals/jama/fullarticle/2853396
The implantable cardioverter-defibrillator (ICD) remains a cornerstone therapy for the prevention of sudden cardiac death. Randomized clinical trials have demonstrated a survival benefit with ICDs for primary prevention in patients with a left ventricular ejection fraction (LVEF) of 35% or less; therefore, professional guideline recommendations on ICDs are based on this LVEF cutoff. However, most individuals who experience a sudden cardiac arrest do not have significant left ventricular dysfunction. Admittedly, these LVEF cutoffs are arbitrary, and the risk of sudden cardiac death is not dichotomous. | 359 |
| 9 | AI-Enabled Aortic Stenosis Screening
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853493
This diagnostic study develops and validates a deep learning algorithm to detect moderate or greater aortic stenosis and prospectively evaluates its performance using artificial intelligence–guided focused cardiac ultrasound acquired by novice operators. | 484 |
| 10 | AI and Echocardiography
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853494
There is a burden of undiagnosed aortic stenosis (AS) in the community—1% of older individuals—which is small but important. This problem has increased with population aging, and the desirability of detection has increased with access to percutaneous management of AS. The limitations of current practice—based on case finding by symptoms, examination findings, or known risk factors—are reflected in the patients who present in extremis from undiagnosed AS and with cardiac damage from prolonged pressure load. However, efforts to screen for AS have been stymied by variability in auscultation accuracy. While the enhancement of electrocardiography by artificial intelligence (AI) might help, this technique is still in development and validation. A combined approach of AI-guided transthoracic echocardiography (TTE) acquisition and interpretation might provide an inexpensive initial screening test that triages no significant AS from possible or uncertain AS, which then leads to comprehensive TTE, surveillance, and intervention. | 495 |
| 11 | Nomenclature
https://jamanetwork.com/journals/jama/fullarticle/2853365
In this narrative medicine essay, a maternal-fetal medicine physician trained to use clinical terms for developmental stages of pregnancy as an emotional stay against an uncertain outcome experiences tension between clinical and lived language during his wife’s miscarriage. | 500 |
| 12 | ADVOCATing for Patients With Heart Failure
https://jamanetwork.com/journals/jama/fullarticle/2853366
The ADVOCATE initiative and how autonomous AI agents could help patients with heart failure are discussed by JAMA+ AI Editor in Chief Roy Perlis, MD, MSc, and Haider Warraich, MD, a cardiologist and the program manager at ARPA-H, for the JAMA+ AI Conversations podcast. | 483 |
| 13 | Parental Support Package for Pregnant and Postpartum Trainees—Reply
https://jamanetwork.com/journals/jama/fullarticle/2853367
In Reply We share the conviction of Dr Patek and colleagues that parental leave is critically important for the well-being of childbearing trainees. We believe, however, that burnout among childbearing trainees is multifactorial, and the empirical evidence does not support paid parental leave as the single most important intervention to reduce burnout in this population. While foundational, leave policies do not address many stressors that emerge during pregnancy or after trainees return to clinical work. As Patek and colleagues note, regardless of leave duration, trainees ultimately transition back to work, and support is needed when they do. | 492 |
| 14 | Parental Support Package for Pregnant and Postpartum Trainees
https://jamanetwork.com/journals/jama/fullarticle/2853368
To the Editor The recent article on a pragmatic parental support package to mitigate burnout among pregnant and postpartum trainees addressed a real and underrecognized problem. However, the proposed parental support package did not address the structural determinants of burnout in this population, and framing it as a meaningful solution risks diverting attention from reforms with greater demonstrated impact. | 428 |
| 15 | Foreign Letters
https://jamanetwork.com/journals/jama/fullarticle/2853369 | 405 |
| 16 | Amoxicillin-Clavulanate vs Amoxicillin for Sinusitis
https://jamanetwork.com/journals/jama/fullarticle/2853349
To the Editor Dr Savage and colleagues reported no difference in treatment failure between standard-dose amoxicillin-clavulanate and amoxicillin among adults aged 18 to 64 years treated for outpatient acute sinusitis, whereas amoxicillin-clavulanate was associated with higher risks of yeast infection and Clostridioides difficile infection. These findings are important for antimicrobial stewardship and support narrower-spectrum therapy when antibiotics are indicated for uncomplicated acute sinusitis. | 651 |
| 17 | Amoxicillin-Clavulanate vs Amoxicillin for Sinusitis
https://jamanetwork.com/journals/jama/fullarticle/2853350
To the Editor The retrospective cohort study by Dr Savage and colleagues compared outcomes of narrow- vs broader-spectrum antibiotics for acute sinusitis. Although the authors’ findings support use of amoxicillin when antibiotics are prescribed, the underlying assumption that most patients truly had acute bacterial sinusitis warrants closer scrutiny. | 611 |
| 18 | Cannabinoid Hyperemesis Syndrome
https://jamanetwork.com/journals/jama/fullarticle/2853351
This JAMA Insights discusses cannabinoid hyperemesis syndrome, including pathophysiology, clinical presentation, and the epidemiology and risk factors. | 562 |
| 19 | Revised Supplement 2
https://jamanetwork.com/journals/jama/fullarticle/2853352
The Original Investigation titled “Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis,” published on October 3, 2023, was corrected to update Supplement 2. In the original supplement, eTable 21 and eTable 22 were identical and did not have the correct information. This article was corrected online. | 491 |
| 20 | Venous Thromboembolism Risk and Lipid-Lowering Therapy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853339
To the Editor The post hoc analysis of the CLEAR Outcomes trial by Spiazzi and colleagues provides a clinically stimulating observation: bempedoic acid was associated with a 42% relative reduction in venous thromboembolism (VTE) among statin-intolerant patients at high cardiovascular risk or with established cardiovascular disease. This quantitative signal is particularly relevant because VTE, encompassing deep vein thrombosis and pulmonary embolism, remains a frequent and potentially severe condition, associated with substantial morbidity, mortality, recurrence, and health care burden. | 518 |
